Pulmonary and Ventilatory Effects of Bed Verticalization in Patients With Acute Respiratory Distress Syndrome (ERECTION)

Pulmonary and Ventilatory Effects of Bed Verticalization in Patients With Acute Respiratory Distress Syndrome: An Exploratory and Pathophysiology Study

Acute respiratory distress syndrome (ARDS) is defined using the clinical criteria of bilateral pulmonary opacities on a chest radiograph, arterial hypoxemia (partial pressure of arterial oxygen [PaO2] to fraction of inspired oxygen [FiO2] ratio ≤ 300 mmHg with positive end-expiratory pressure [PEEP] ≥ 5 cmH2O) within one week of a clinical insult or new or worsening respiratory symptoms, and the exclusion of cardiac failure as the primary cause. ARDS is a fatal condition for intensive care unit (ICU) patients with a mortality between 30 and 40%, and a frequently under-recognized challenge for clinicians. Patients with severe symptoms may retain sequelae that have recently been reported in the literature. These sequelae may include chronic respiratory failure, disabling neuro-muscular disorders, and post-traumatic stress disorder identical to that observed in soldiers returning from war.

The management of a patient with ARDS requires first of all an optimization of oxygenation, which relies primarily on mechanical ventilation, whether invasive or non-invasive (for less severe patients). Since the ARDS network study published in 2000 in the New England Journal of Medicine, it has been internationally accepted that tidal volumes must be reduced in order to limit the risk of alveolar over-distension and ventilator-induced lung injury (VILI). A tidal volume of approximately 6 mL.kg-1 ideal body weight (IBW) should be applied. Routine neuromuscular blockade of the most severe patients (PaO2/FiO2 < 120 mmHg) is usually the rule, although it is increasingly being questioned. Comprehensive ventilatory management is based on the concepts of baby lung and open lung, introduced respectively by Gattinoni and Lachmann. According to these concepts, it must be considered that the lung volume available for mechanical ventilation is very small compared to the healthy lung for a given patient (baby lung) and that the reduction in tidal volume must be associated with the use of sufficient PEEP and alveolar recruitment maneuvers to keep the lung "open" and limit the formation of atelectasis.

In addition to this optimization of mechanical ventilation, it is possible to reduce the impact of mechanical stress on the lung. The prone position, for example, makes it possible to free from certain visceral and mediastinal constraints, to optimize the distribution of ventilation as well as the ventilation to perfusion ratios.

Thanks to the technological progress of intensive care beds, it is now possible to verticalize ventilated and sedated patients in complete safety. Verticalization could reduce the constraints imposed to the lungs, by reproducing the more physiological vertical station, and thus modifying the distribution of ventilation.

Indeed, in two physiological studies published in 2006 and 2013 in Intensive Care Medicine, 30 to 40% of patients with ARDS appeared to respond to partial body verticalization at 45° and 60° (in a semi-seated or seated position). In addition to improving arterial oxygenation, verticalization appeared to decrease ventilatory stress, related to supine position, and increase alveolar recruitment, with improved lung compliance and end-expiratory lung volume (EELV) over time. Nevertheless, 90° verticalization has never been studied, nor have positions without body flexion (seated or semi-seated). In these studies, only patients with the highest lung compliance appeared to respond. These data support the current hypothesis of subgroups of patients with ARDS with different pathophysiological characteristics (morphological and phenotypic) and therapeutic responses.

The investigators hypothesize that verticalization of patients with ARDS improves ventilatory mechanics by reducing the constraints imposed on the lung (transpulmonary pressure), pulmonary aeration, arterial oxygenation and ventilatory parameters.

The first objective is to study the influence of the bed position of the patient with early ARDS on the variations in respiratory mechanics represented by the transpulmonary driving pressure (ΔPtp). The second objective is to evaluate changes in ventilatory physiology, tolerance and feasibility of verticalization in patients with early ARDS.

Study Overview

• Status: Completed
• Conditions: Acute Respiratory Distress Syndrome
• Intervention / Treatment: Other: Verticalization (bed)

Detailed Description

This is an interventional study evaluating the beneficial impact of verticalization of patients with ARDS on pathophysiological parameters.

This therapeutic study aims to test patient's position using dedicated beds (Total Lift Bed™, VitalGo Systems Inc., Arjo AB). The study consists of comparing pulmonary pathophysiological parameters for different positions (from the strict dorsal decubitus to the vertical, with 30° and 60° steps) in patients with early ARDS of focal and non-focal morphologies, under invasive mechanical ventilation.

The primary outcome is the difference between the transpulmonary driving pressure (ΔPtp) measured at the end of each verticalization step (30th minute) and the basal value measured at the beginning of the protocol, in strict dorsal decubitus (0°).

The minimum number of subjects to enroll in this study is 30 patients with early ARDS, including 15 with focal lung morphology and 15 with non-focal lung morphology. Intermediate analyses are planned every 5 patients in order to reevaluate the needed number of patients.

The use of a dedicated bed (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB) allows the verticalization of patients under sedation and mechanical ventilation up to 90°. The procedure foresees the gradual verticalization of the patients of 0°, 30°, 60° and 90° by steps of 30 minutes. At the end of each position step (0°, 30°, 60° and 90°), measurement of end-expiratory lung impedance (EELI) and chest electrical impedance tomography (EIT) parameters, measurement of esophageal pressures, collection of ventilatory parameters on the ventilator, collection of Swan-Ganz catheter hemodynamic data, measurement of lung shunt by mixed venous and arterial blood gas analyses and measurement of end-expiratory lung volume (EELV) by the N2 washin-washout method.

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Clermont-Ferrand, France, 63000
    • CHU

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient with moderate or severe Acute Respiratory Distress Syndrome (ARDS) (PaO2/FiO2 < 200 mmHg), at their early phase (< 12h), under invasive mechanical ventilation with controlled ventilation (intubation or tracheotomy).
• Patient equipped with an arterial catheter.
• Patient sedated (BIS between 30 and 50) and, if necessary, under neuromuscular blocking agent (TOF < 2/4 at the orbicular) to avoid inspiratory effort.
• Patient hemodynamically optimized following the Swan-Ganz catheter data.

Exclusion Criteria:

• Refusal to participate in the proposed study.
• Unavailability of the bed dedicated to verticalization (Total Lift Bed™, VitalGo Systems Inc., Arjo AB)
• Obesity with BMI ≥ 35 kg.m-2
• Significant hemodynamic instability defined as an increase of more than 20% in catecholamine doses in the last hour, despite optimization of blood volume, for a target mean blood pressure between 65 and 75 mmHg.
• Contraindication to the insertion of a nasogastric tube
• Contraindication to the use of the chest electrical impedance tomography
• Contraindication to the insertion of a Swan-Ganz catheter
• Contraindication to the application of compression stockings
• Patient under guardianship
• Pregnancy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Verticalization group; After checking the availability of the bed dedicated to verticalization (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB), the inclusion and non-inclusion criteria, as well as the morphology of lung injury, the patient is included. The following procedures are performed : insertion of an esophageal balloon catheter (Nutrivent®, Sidam); installation of an EIT belt in the 4th or 5th intercostal space (Pulmovista® 500, Dräger); insertion of a Swan-Ganz catheter; continuous recording of digital and analogic data After collecting initial data from the patient in a strict lying position at 0°, successive 30-minutes position steps at 30°, 60° and 90° will be performed. At the end of the 30 minutes, and for each step, all the data is collected.

Other: Verticalization (bed); The use of a dedicated bed (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB) allows the verticalization of patients under sedation and mechanical ventilation up to 90°. The procedure foresees the gradual verticalization of the patients of 0°, 30°, 60° and 90° by steps of 30 minutes. At the end of each position step (0°, 30°, 60° and 90°), measurement of end-expiratory lung impedance (EELI) and chest electrical impedance tomography (EIT) parameters, measurement of esophageal pressures, collection of ventilatory parameters on the ventilator, collection of Swan-Ganz catheter hemodynamic data, measurement of lung shunt by mixed venous and arterial blood gas analyses and measurement of end-expiratory lung volume (EELV) by the N2 washin-washout method

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Transpulmonary driving pressure (ΔPtp)	Difference between the transpulmonary driving pressure (ΔPtp) measured at the end of each verticalization step (30th minute) and the basal value measured at the beginning of the protocol, in strict dorsal decubitus (0°).	At the end of each verticalization step (30th minute)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pulmonary mechanics	Maximal transpulmonary pressure (alveolar stress)	Baseline
Pulmonary mechanics	Maximal transpulmonary pressure (alveolar stress)	At the end of each verticalization step (30th minute)
Pulmonary mechanics	Alveolar strain (Vt/EELV)	Baseline
Pulmonary mechanics	Alveolar strain (Vt/EELV)	At the end of each verticalization step (30th minute)
Pulmonary mechanics	Driving pressure	Baseline
Pulmonary mechanics	Driving pressure	At the end of each verticalization step (30th minute)
Pulmonary mechanics	Transpulmonary driving pressure	Baseline
Pulmonary mechanics	Transpulmonary driving pressure	At the end of each verticalization step (30th minute)
Pulmonary mechanics	Dead space (Vd/Vt)	Baseline
Pulmonary mechanics	Dead space (Vd/Vt)	At the end of each verticalization step (30th minute)
Pulmonary mechanics	Pulmonary compliance	Baseline
Pulmonary mechanics	Pulmonary compliance	At the end of each verticalization step (30th minute)
Pulmonary mechanics	Pressure-volume curves	Baseline
Pulmonary mechanics	Pressure-volume curves	At the end of each verticalization step (30th minute)
Pulmonary mechanics	Recruitable volume	Baseline
Pulmonary mechanics	Recruitable volume	At the end of each verticalization step (30th minute)
Pulmonary mechanics	Optimal PEEP (best compliance)	Baseline
Pulmonary mechanics	Optimal PEEP (best compliance)	At the end of each verticalization step (30th minute)
Pulmonary mechanics	O2 consumption (VO2)	Baseline
Pulmonary mechanics	O2 consumption (VO2)	At the end of each verticalization step (30th minute)
Pulmonary mechanics	CO2 production (VCO2)	Baseline
Pulmonary mechanics	CO2 production (VCO2)	At the end of each verticalization step (30th minute)
Pulmonary mechanics	Pulmonary shunt	Baseline
Pulmonary mechanics	Pulmonary shunt	At the end of each verticalization step (30th minute)
Pulmonary mechanics	Mechanical power imparted to patient's lungs by ventilator	Baseline
Pulmonary mechanics	Mechanical power imparted to patient's lungs by ventilator	At the end of each verticalization step (30th minute)
Chest electrical impedance tomography (EIT)	Center Of Ventilation (COV)	Baseline
Chest electrical impedance tomography (EIT)	Center Of Ventilation (COV)	At the end of each verticalization step (30th minute)
Chest electrical impedance tomography (EIT)	Tidal Impedance Variation (TIV)	Baseline
Chest electrical impedance tomography (EIT)	Tidal Impedance Variation (TIV)	At the end of each verticalization step (30th minute)
Chest electrical impedance tomography (EIT)	Regional Ventilation Delay (RVD)	Baseline
Chest electrical impedance tomography (EIT)	Regional Ventilation Delay (RVD)	At the end of each verticalization step (30th minute)
Chest electrical impedance tomography (EIT)	End Expiratory Lung Impedance (EELI)	Baseline
Chest electrical impedance tomography (EIT)	End Expiratory Lung Impedance (EELI)	At the end of each verticalization step (30th minute)
Chest electrical impedance tomography (EIT)	Percentages of over-distended and collapsed alveolar regions.	Baseline
Chest electrical impedance tomography (EIT)	Percentages of over-distended and collapsed alveolar regions.	At the end of each verticalization step (30th minute)
Hemodynamics	Heart rate	Baseline
Hemodynamics	Heart rate	At the end of each verticalization step (30th minute)
Hemodynamics	Invasive systolic blood pressure	Baseline
Hemodynamics	Invasive systolic blood pressure	At the end of each verticalization step (30th minute)
Hemodynamics	Invasive mean blood pressure	Baseline
Hemodynamics	Invasive mean blood pressure	At the end of each verticalization step (30th minute)
Hemodynamics	Invasive diastolic blood pressure	Baseline
Hemodynamics	Invasive diastolic blood pressure	At the end of each verticalization step (30th minute)
Hemodynamics	Continuous cardiac output	Baseline
Hemodynamics	Continuous cardiac output	At the end of each verticalization step (30th minute)
Hemodynamics	Pulmonary systolic arterial pressures	Baseline
Hemodynamics	Pulmonary systolic arterial pressures	At the end of each verticalization step (30th minute)
Hemodynamics	Pulmonary mean arterial pressures	Baseline
Hemodynamics	Pulmonary mean arterial pressures	At the end of each verticalization step (30th minute)
Hemodynamics	Pulmonary diastolic arterial pressures	Baseline
Hemodynamics	Pulmonary diastolic arterial pressures	At the end of each verticalization step (30th minute)
Hemodynamics	Pulmonary vascular resistance	Baseline
Hemodynamics	Pulmonary vascular resistance	At the end of each verticalization step (30th minute)
Hemodynamics	Pulmonary artery occlusion pressure	Baseline
Hemodynamics	Pulmonary artery occlusion pressure	At the end of each verticalization step (30th minute)
Hemodynamics	Systolic ejection volume	Baseline
Hemodynamics	Systolic ejection volume	At the end of each verticalization step (30th minute)
Hemodynamics	SvO2	Baseline
Hemodynamics	SvO2	At the end of each verticalization step (30th minute)
Hemodynamics	End-diastolic volume	Baseline
Hemodynamics	End-diastolic volume	At the end of each verticalization step (30th minute)
Hemodynamics	Systemic vascular resistance	Baseline
Hemodynamics	Systemic vascular resistance	At the end of each verticalization step (30th minute)
Hemodynamics	Right ventricular end-diastolic volume	Baseline
Hemodynamics	Right ventricular end-diastolic volume	At the end of each verticalization step (30th minute)
Hemodynamics	Right ventricular ejection fraction	Baseline
Hemodynamics	Right ventricular ejection fraction	At the end of each verticalization step (30th minute)
Blood gases	Arterial and mixed venous blood gases data (PaO2, PaCO2, SaO2, SvO2).	Baseline
Blood gases	Arterial and mixed venous blood gases data (PaO2, PaCO2, SaO2, SvO2).	At the end of each verticalization step (30th minute)

Collaborators and Investigators

• Sponsor: University Hospital, Clermont-Ferrand
• Investigators: Study Chair: Jules Audard, University Hospital, Clermont-Ferrand

Study record dates

Study Major Dates

• Study Start (Actual): March 30, 2020
• Primary Completion (Actual): January 14, 2021
• Study Completion (Actual): January 14, 2021

Study Registration Dates

• First Submitted: April 24, 2020
• First Submitted That Met QC Criteria: April 28, 2020
• First Posted (Actual): May 1, 2020

Study Record Updates

• Last Update Posted (Actual): August 25, 2021
• Last Update Submitted That Met QC Criteria: August 24, 2021
• Last Verified: June 1, 2020

More Information

Terms related to this study

• Keywords: Intensive Care Unit; Mechanical Ventilation; Acute Respiratory Distress Syndrome; Verticalization
• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Respiration Disorders; Lung Diseases; Disease; Infant, Newborn, Diseases; Lung Injury; Infant, Premature, Diseases; Syndrome; Respiratory Distress Syndrome; Respiratory Distress Syndrome, Newborn; Acute Lung Injury
• Other Study ID Numbers: RBHP AUDARD 2019

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No